Multiple Sclerosis
Conference Coverage
Even with no disease activity, recurrence risk near 50% when stopping DMTs for MS
STOCKHOLM – Younger patients had a significantly higher risk of recurrence when stopping disease modifying therapy.
Conference Coverage
Plasma exchange in natalizumab-related PML shows no benefit, possible harm
STOCKHOLM – Biggest-ever study of natalizumab-associated PML in patients with multiple sclerosis raises red flag regarding common practice of...
Conference Coverage
Ofatumumab has superior efficacy in relapsing-remitting MS, compared with teriflunomide
STOCKHOLM – The monoclonal antibody reduced annualized relapse rate and the risk of confirmed disability worsening,...
Conference Coverage
Newer drugs provide superior disease activity control in pediatric MS
STOCKHOLM – Study from U.S. Network of Pediatric MS Centers supports early use of newer disease-modifying therapies.
Conference Coverage
Inebilizumab looks good for neuromyelitis optica in phase 2/3 trial
STOCKHOLM – Attacks were significantly reduced and a marker for tissue damage dropped, but IgG levels will likely have to be tracked long term.
Conference Coverage
Average daily step count reflects disability in MS
STOCKHOLM – Step count can be monitored remotely and correlates with measures of walking performance, cognitive...
Conference Coverage
In highly active MS, is skipping gadolinium an option?
STOCKHOLM – Though skipping contrast missed a small number of lesions, most patients would still have been classified and treated correctly.
Conference Coverage
Most patients with RIS develop MS within 10 years
STOCKHOLM – The conversion rate jumps to 87% in the presence of four risk factors at baseline.
Conference Coverage
In MS, iron-ringed lesions may add to imaging toolkit
STOCKHOLM – Brain lesions with iron rings were detected only in MRI scans of MS patients.
Conference Coverage
Ponesimod reduces annualized relapse rate, compared with teriflunomide
STOCKHOLM – The investigational MS treatment is superior to the approved drug on measures of fatigue and active...
Conference Coverage
Continuous treatment reduces risk of confirmed disability progression in MS
STOCKHOLM – The risk of confirmed disability progression appears to decrease with increasing length of continuous...